See more : Kotak Mahindra Bank Limited (KOTAKBANK.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Zymeworks Inc. (ZYME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zymeworks Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Sparindex INDEX Nye Obl.mark Ak (SPVINOAKKKLA.CO) Income Statement Analysis – Financial Results
- JETEMA, Co., Ltd. (216080.KQ) Income Statement Analysis – Financial Results
- TH Plantations Berhad (5112.KL) Income Statement Analysis – Financial Results
- Sibar Auto Parts Limited (SIBARAUT.BO) Income Statement Analysis – Financial Results
- Zai Lab Limited (ZLAB) Income Statement Analysis – Financial Results
Zymeworks Inc. (ZYME)
About Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.01M | 412.48M | 26.68M | 38.95M | 29.54M | 53.02M | 51.76M | 11.01M | 9.66M | 1.67M |
| Cost of Revenue | 142.99M | 208.70M | 199.54M | 170.90M | 117.10M | 56.93M | 41.14M | 35.55M | 24.40M | 10.47M |
| Gross Profit | -66.98M | 203.78M | -172.86M | -131.95M | -87.55M | -3.91M | 10.62M | -24.54M | -14.74M | -8.80M |
| Gross Profit Ratio | -88.11% | 49.40% | -647.90% | -338.75% | -296.34% | -7.37% | 20.51% | -222.93% | -152.62% | -527.13% |
| Research & Development | 143.62M | 208.60M | 199.75M | 168.53M | 115.90M | 56.68M | 41.75M | 36.82M | 24.65M | 12.62M |
| General & Administrative | 70.45M | 73.36M | 42.56M | 57.89M | 64.18M | 29.46M | 18.55M | 12.55M | 5.22M | 3.95M |
| Selling & Marketing | -46.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 70.40M | 73.36M | 42.56M | 57.89M | 64.18M | 29.46M | 18.55M | 12.55M | 5.22M | 3.95M |
| Other Expenses | -142.94M | 4.71M | 3.27M | 7.35M | 5.28M | -1.26M | -964.00K | -1.27M | -251.00K | -2.15M |
| Operating Expenses | 71.08M | 281.95M | 242.31M | 226.42M | 180.08M | 86.15M | 59.22M | 48.11M | 29.62M | 14.42M |
| Cost & Expenses | 214.07M | 281.95M | 242.31M | 226.42M | 180.08M | 86.15M | 59.22M | 48.11M | 29.62M | 14.42M |
| Interest Income | 19.71M | 3.60M | 1.97M | 5.70M | 6.02M | 2.64M | 743.00K | 308.00K | 324.00K | 116.00K |
| Interest Expense | 0.00 | 3.60M | 0.00 | 0.00 | 0.00 | 166.00K | 892.00K | 950.00K | 18.00K | 9.00K |
| Depreciation & Amortization | 17.31M | 12.00M | 9.58M | 10.28M | 7.33M | 3.63M | 2.74M | 1.03M | 494.00K | 412.00K |
| EBITDA | -129.96M | 147.24M | -206.09M | -177.17M | -143.19M | -30.76M | -6.08M | -36.26M | -18.62M | -12.34M |
| EBITDA Ratio | -170.97% | 31.64% | -808.22% | -481.29% | -506.92% | -62.48% | -11.45% | -329.37% | -198.16% | -749.28% |
| Operating Income | -138.05M | 130.53M | -215.63M | -187.47M | -151.30M | -33.13M | -9.00M | -37.86M | -19.96M | -12.75M |
| Operating Income Ratio | -181.62% | 31.64% | -808.22% | -481.29% | -512.12% | -62.48% | -17.38% | -343.94% | -206.63% | -763.35% |
| Total Other Income/Expenses | 18.81M | 4.71M | 3.27M | 7.35M | 5.28M | -1.02M | -964.00K | -1.02M | 824.00K | -194.00K |
| Income Before Tax | -119.24M | 135.23M | -212.36M | -180.12M | -146.02M | -34.39M | -9.96M | -38.88M | -19.14M | -12.94M |
| Income Before Tax Ratio | -156.87% | 32.79% | -795.95% | -462.43% | -494.24% | -64.85% | -19.25% | -353.20% | -198.10% | -774.97% |
| Income Tax Expense | -568.00K | 10.89M | -516.00K | 429.00K | -582.00K | 2.17M | 444.00K | -5.08M | 34.00K | -284.00K |
| Net Income | -118.67M | 124.34M | -211.84M | -180.55M | -145.44M | -36.56M | -10.41M | -33.81M | -19.17M | -12.94M |
| Net Income Ratio | -156.13% | 30.14% | -794.01% | -463.54% | -492.27% | -68.95% | -20.10% | -307.10% | -198.45% | -774.97% |
| EPS | -1.72 | 1.91 | -4.06 | -3.58 | -3.83 | -1.26 | -0.49 | -1.72 | -0.97 | -0.65 |
| EPS Diluted | -1.72 | 1.90 | -4.06 | -3.58 | -3.83 | -1.26 | -0.49 | -1.72 | -0.97 | -0.65 |
| Weighted Avg Shares Out | 68.86M | 65.19M | 52.13M | 50.38M | 37.97M | 29.01M | 21.25M | 19.70M | 19.84M | 19.84M |
| Weighted Avg Shares Out (Dil) | 68.86M | 65.25M | 52.13M | 50.38M | 38.02M | 29.09M | 21.32M | 19.70M | 19.84M | 19.84M |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
Zymeworks Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ZYME
Zymeworks Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - ZYME
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock?
Next-Gen Winners: 7 Tech Stocks Set to Dominate the Decade
Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
Source: https://incomestatements.info
Category: Stock Reports